Price$28.22-0.25 (-0.88%)
01:45 PM07:45 PM
News · 26 weeks82+233%
2025-12-072026-05-31
Mix2490d
- Insider12(50%)
- SEC Filings5(21%)
- Other4(17%)
- Analyst2(8%)
- Earnings1(4%)
Latest news
25 items- PRSTAAR Surgical Announces Participation in Upcoming Investor ConferencesSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcast: 4:30 PM ET, Webcast Link Canaccord Genuity Virtual Fireside Chat Date: Wednesday, May 27, 2026 Format: Webcast Fireside Chat Details: Registration for the webcast is by invitation only via the sponsoring brokerage firm. Webcast: 2:3
- INSIDERChief Development Officer Michna Magda was granted 19,795 shares and covered exercise/tax liability with 9,703 shares, increasing direct ownership by 31% to 42,783 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERInterim Co-CEO and CFO Andrews Deborah J was granted 15,699 shares and covered exercise/tax liability with 5,632 shares (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERInterim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 16,785 shares and was granted 32,990 shares, increasing direct ownership by 24% to 83,112 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- ANALYSTSTAAR Surgical upgraded by Wedbush with a new price targetWedbush upgraded STAAR Surgical from Neutral to Outperform and set a new price target of $40.00
- SECSEC Form 10-Q filed by STAAR Surgical Company10-Q - STAAR SURGICAL CO (0000718937) (Filer)
- SECSTAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - STAAR SURGICAL CO (0000718937) (Filer)
- PRSTAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder LetterNet Sales of $93.5 million, highest first quarter Net Sales in Company's history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $
- INSIDERInterim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 3,448 shares, decreasing direct ownership by 5% to 66,917 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERChief Development Officer Michna Magda covered exercise/tax liability with 1,680 shares, decreasing direct ownership by 5% to 32,691 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- SECSEC Form DEFA14A filed by STAAR Surgical CompanyDEFA14A - STAAR SURGICAL CO (0000718937) (Filer)
- SECSEC Form DEF 14A filed by STAAR Surgical CompanyDEF 14A - STAAR SURGICAL CO (0000718937) (Filer)
- PRSTAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in combination with a shareholder letter for the first quarter ended April 3, 2026, on Wednesday, May 13, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical First Quarter 2026 Financial Results Webcast Date: Wednesday, May 13, 2026 Time: 5:30 p.m. ET/ 2:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=bNZKMWPv M
- ANALYSTSTAAR Surgical upgraded by Canaccord Genuity with a new price targetCanaccord Genuity upgraded STAAR Surgical from Hold to Buy and set a new price target of $27.00
- SECSTAAR Surgical Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - STAAR SURGICAL CO (0000718937) (Filer)
- PRSTAAR Surgical Announces Preliminary Net Sales for First Quarter 2026STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of the ophthalmology community, at the ASCRS Annual Meeting in Washington, D.C. Net sales for the first quarter of 2026 are expected to be in excess of $90 million, compared to net sales of $42.6 million for the first quarter of 2025. "We
- SECAmendment: SEC Form SCHEDULE 13G/A filed by STAAR Surgical CompanySCHEDULE 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
- INSIDERInterim Co-CEO and Pres. & COO Foust Warren converted options into 37,500 shares, increasing direct ownership by 144% to 63,588 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERChief Development Officer Michna Magda converted options into 23,773 shares and covered exercise/tax liability with 8,529 shares, increasing direct ownership by 105% to 29,668 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERDirector Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by STAAR Surgical Company4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by Director Lebuhn Richard T.4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by STAAR Surgical Company4 - STAAR SURGICAL CO (0000718937) (Issuer)
- SECSTAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - STAAR SURGICAL CO (0000718937) (Filer)
STAA FAQ
6 questionsWhat does STAAR Surgical Company do?
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related...Where does STAA stock trade?
STAAR Surgical Company (STAA) is listed on NASDAQ.What sector and industry is STAA in?
STAAR Surgical Company operates in the Health Care sector, Ophthalmic Goods industry.What are analysts saying about STAA?
STAAR Surgical Company has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $4000.00 price target on 2026-05-14. Recent price targets range from $1300.00 to $4000.00.What companies are similar to STAA?
Notable peers in the same industry include ALC (Alcon Inc.), COO (The Cooper Companies Inc.), BLCO (Bausch + Lomb Corporation), WRBY (Warby Parker Inc.), EYE (National Vision Holdings Inc.). Compare STAA side-by-side with any of them on Quantisnow.How can I track STAA on Quantisnow?
Quantisnow aggregates STAAR Surgical Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STAA to receive live email and push alerts on every new disclosure.